Pergamum and Cadila Pharmaceuticals have entered into a strategic collaboration for the development of a new therapeutic peptide targeting infections using a distinctive mechanism.
The collaboration will focus on preclinical and clinical development of therapeutic peptide, developed by Pergamum, with both anti-infective and anti-inflammatory properties.
Development activities will be carried out at Cadila facilities located in Ahmedabad, India.
Cadila chairman and managing director Rajiv Modi said, "This partnership combines Cadila's advanced product development capabilities with the innovative capacity of Pergamum. Cadila Pharmaceuticals bring their expertise in drug development and demonstrates that commitment towards developing affordable innovative compounds to the market in this collaboration."
According to the deal, Cadila is responsible for costs associated with the product development till Phase II while worldwide rights will be shared between the companies.